N-terminal heterogeneity of parenchymal and cerebrovascular aβ deposits

Journal of Neuropathology and Experimental Neurology

Volumn 57, Issue 1, 1998, Pages 76-94

  Tekirian, Tina L ^a   Saido, Takaomi C ^b   Markesbery, William R ^a   Russell, Michael J ^c   Wekstein, David R ^a   Patel, Ela ^a   Geddes, James W ^a,d  

^a UNIVERSITY OF KENTUCKY   (United States)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer disease; Canine; Human; Polar bear

Indexed keywords

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BEAR; DOG; HUMAN; NONHUMAN; PRIORITY JOURNAL; SENILE PLAQUE;

EID: 0031985080     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005072-199801000-00009     Document Type: Article

References (78)

1. Hamill RW, Markesbery WR, McDaniel K, Coleman PD. Characterization of brain samples in studies of aging, Alzheimer's, and other neurodegenerative diseases. Neurobiol Aging 1993;14:539-45
2. Kuo YM, Emmerling MR, Vigo-Pelfrey C, et al. Water-soluble ABeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 1996;271:4077-81
3. Pike CJ, Walencewicz AJ, Glabe CG, Cotman CW. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res 1991;563:311-14
4. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by β-amyloid peptides in vitro: The role of peptide assembly state. J Neuroscience 1993;13:1676-87
5. Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated beta-amyloid peptide are attenuated by basic FGF. Brain Res 1993;621:35-49
6. Lorenzo A, Yankner BA. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc Natl Acad Sci USA 1994;91:12243-47
7. Yamaguchi H, Nakazato Y, Shoji M, Takatama M, Hirai S. Ultrastructure of diffuse plaques in senile dementia of the Alzheimer type: Comparison with primitive plaques. Acta Neuropathologica 1991;82:13-20
8. Davies CA, Mann DM. Is the "preamyloid" of diffuse plaque in Alzheimer's disease really nonfibrillar? Amer J Pathol 1993;143: 1594-1605
9. Selkoe DJ, Beli DS, Podlisny MB, Price DL, Cork LC. Conservation of brain amyloid proteins in aged mammals and humans with Alzheimer's disease. Science 1987:235:873-77
10. Cork LC, Masters C, Beyreuther K, Price DL. Development of senile plaques. Relationships of neuronal abnormalities and amyloid deposits. Amer J Pathol 1990;137:1383-92
11. Martin LJ, Sisodia SS, Koo EH, et al. Amyloid precursor protein in aged nonhuman primates. PNAS (USA) 1991;88:1461-65
12. Robakis NK, Pangalos MN. Involvement of amyloid as a central step in the development of Alzheimer's disease. Neurobiol Aging 1994;15:S127-S129
13. Tagliavini F, Ghiso J, Timmers WF, Giaccone G, Bugiani O, Frangione B. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest 1990;62:761-67
14. Johnstone EM, Chaney MO, Norris FH, Pascual R, Little SP. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear, and five other mammals by cross-species polymerase chain reaction analysis. Brain Res Mol Brain Res 1991; 10:299-305
15. Wisniewski T, Lalowski M, Bobik M, Russell M, Strosznajder J, Frangione B. Amyloid β1-42 deposits do not lead to Alzheimer's neuritic plaques in aged dogs. Biochem J 1996;313:575-80
16. Cummings BJ, Sato T, Head E, et al. Diffuse plaques contain C-terminal Aβ42 and not Aβ40: Evidence from cats and dogs. Neurobiol Aging 1996;17:653-59
17. Tekirian TL, Cole GM, Russell MJ, et al. Carboxy terminal of β-amyloid deposits in aged human, canine, and polar bear brains. Neurobiology of Aging 1996;17:249-57
18. Walker LC, Masters C, Beyreuther K, Price DL. Amyloid in the brains of aged squirrel monkeys. Acta Neuropathologica 1990;80: 381-87
19. Heilbroner PL, Kemper TL. The cytoarchitectonic distribution of senile plaques in three aged monkeys. Acta Neuropathol 1990;81: 60-65
20. Martin LJ, Pardo CA, Cork LC, Price DL. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aged cerebral cortex. Amer J Pathol 1994;145:1358-81
21. Bons N, Mestre N, Ritchie K, Petter A, Podlisny M, Selkoe D. Identification of amyloid beta protein in the brain of the small, short-lived Lemurian primate Microcebus murinus. Neurobiol Aging 1994;15:215-20
22. Geddes JW, Anderson KJ, Cotman CW. Senile plaques as aberrant sprout-stimulating structures. Exp Neurol 1986;94:767-76
23. Grain BJ, Burger PC. The laminar distribution of neuritic plaques in the fascia dentata of patients with Alzheimer's disease. Acta Neuropathol (Berl) 1988;76:87-93
24. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 1995;373:523-52
25. Checler F. Processing of the β-amyloid precursor protein and its regulation in Alzheimer's disease. J. Neurochem 1995;65:1431-43
26. Roher AE, Lowenson JD, Clarke S, et al. Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 1993;268:3072-83
27. Mori H, Takio K, Ogawara M, Selkoe DJ. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J Biol Chem 1992;267:17082-86
28. Kim J, Kim K. The use of FAB mass spectrometry and pyroglutamate aminopeptidase digestion for the structure determination of pyroglutamate in modified peptides. Biochem Mol Biol Internat 1995;35:803-11
29. Barrow CJ, Zagorski MG. Solution structures of β peptide and its constituent fragments: relation to amyloid deposition. Science 1991; 253:179-82
30. Burdick D, Soreghan B, Kwon M, et al. Assembly and aggregation properties of synthetic Alzheimer's A4/β amyloid peptide analogs. J Biol Chem 1992;267:546-54
31. Jarrett JT, Berger EP, Lansbury PT. The carboxy terminus of the β-amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-97
32. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53
33. Pike CJ, Overmann MJ, Cotman CW. Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. J Biol Chem 1995;270:23895-98
34. Saido TC, Iwatsubo T, Mann DMA, Shimada H. Ihara Y, Kawashima S. Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques. Neuron 1995;14: 457-66
35. Gowing E, Roher AE, Woods AS, et al. Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 1994;269:10987-90
36. Mak K, Yang F, Vinters HV, Frautschy SA, Cole GM. Polyclonals to β-amyloid(1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum. Brain Res 1994;667:138-42
37. Yang F, Mak K, Vinters HV, Frautschy SA, Cole GM. Monoclonal antibody to the C-terminus of β-amyloid. Neuroreport 1994;5: 2117-20
38. Iwatsubo T, Saido TC, Mann DMA, Lee VM-Y, Trojanowski JQ. Full-length amyloid β(1-42(43) and amino terminally modified and truncated amyloid β42(43) deposit in diffuse plaques. Amer J Pathol 1996;149:1823-30
39. Higgins LS, Murphy Jr. GM, Forno LS, Catalano R, Cordell B. p3 β-Amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Amer J Pathol 1996;149:585-96
40. Lalowski M, Golabek A, LeMere CA, et al. The "nonamyloidogenic" p3 fragment (Amyloid β17-42) is a major constituent of Down's Syndrome cerebellar preamyloid. J Biol Chem 1996;271: 33623-31
41. Kida E, Wisniewski KE, Wisniewski HM. Early amyloid-β deposits show different immunoreactivity to the amino-and carboxy-terminal regions of β-peptide in Alzheimer's disease and Down's syndrome brain. Neurosci Lett 1995;193:105-8
42. Lemere CA, Blustajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid β-peptides and APOE in Down Syndrome: Implications for initial events in amyloid plaque formation. Neurobiology of Disease 1996; 3:16-32
43. Russo C, Saido TC, DeBusk LM, Tabaton M, Gambetti P, Teller JK. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett 1997; 409:411-16
44. Younkin SG. Evidence that Aβ42 is the real culprit in Alzheimer's disease. Ann Neurol 1995;37:287-88
45. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44
46. Khatchaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 1985;42:1097-1104
47. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's disease (CERAD) Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
48. Kitomoto T, Ogomori K, Tateishi J, Prusiner SB. Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest 1987;57:230-36
49. Smitt PA, Troost D, Louwerse ES, de Jong JM, van Kessel DT, de Leeuw MA. Temporal lobe pathology in amyotrophic lateral sclerosis. Do amyotrophic lateral sclerosis and Alzheimer's disese share a common etiological factor? Clin Neuropathol 1993;12:88-91
50. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S. Amino-and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Neuroscience Letters 1996;215:173-76
51. Yamamoto T, Hirano A. A comparative study of modified Bielschowsky, Bodian, and Thioflavin S stains on Alzheimer's neurofibrillary tangles. Neuropathol Appl Neurobiol 1986;12:3-9
52. Wolman M, Bubis JJ. The cause of the green polarization color of amyloid stained with Congo Red. Histochemie 1965;4:351-56
53. Yamazaki T, Yamaguchi H, Okamoto K, Hirai S. Ultrastructural localization of argyrophilic substances in diffuse plaques of Alzheimer-type dementia demonstrated by methenamine silver staining. Acta Neuropathol 1991;81:540-45
54. Yamaguchi H, Hirai S, Morimatsu M, Shoji M, Harigaya Y. Diffuse type of senile plaques in the brains of Alzheimer's-type dementia. Acta Neuropathol 1988;77:113-19
55. Defigueiredo RJ, Cummings BJ, Mundkur PY, Cotman CW. Color image analysis in neuroanatomical research: Application to senile plaque subtype quantification in Alzheimer's disease. Neurobiol Aging 1995;16:211-23
56. Geddes JW, Tekirian TL, Soultanian NS, Ashford JW, Davis DG, Markesbery WR. Comparison of neuropathologic criteria for the diagnosis of Alzheimer's disease. Neurobiology of Aging 1997. Forthcoming.
57. Barrow CJ, Yasuda A, Kenny PTM, Zagorski MG. Solution conformations and aggregational properties of synthetic amyloid β-peptides of Alzheimer's disease. J Mol Biol 1992;225:1075-93
58. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-39
59. Mann DMA. The pathological association between Down syndrome and Alzheimer's disease. Mech Ageing Dev 1988;43:99-136
60. Masliah E, Sisk A, Mallory M, Mucke L, Schenk D, Games D. Comparison of neurodegenerative pathology in transgenic mice overexpressing V717F β-amyloid precursor protein and Alzheimer's disease. J. Neurosci 1996;16:5795-5811
61. Games D, Carr T, Guido T, et al. Progression of Alzheimer-type neuropathology in PDAPP 717 V->F transgenic mice. Soc Neurosci Abstr 1995;21:258
62. McDonald JK, Barret AJ. Mammalian proteases. London: Academic Press, 1986
63. Naslund J, Jensen M, Tjemburg LO, Thyburg J, Terenius L, Nordstedt C. The metabolic pathway generating p3, an Aβ-peptide fragment, is probably non-amyloidogenic. Biochem Biophys Res Commun 1994;204:780-87
64. Velazquez P, Cribbs DH, Poulos TL, Tenner AJ. Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis. Nat Med 1997;3:77-79
65. Shapira R, Austin GE, Mirra SS. Neuritic plaque amyloid in Alzheimer's disease is highly racemized. J Neurochem 1988;50:69-74
66. Bada L. In vivo racemization in mammalian proteins. In: Wold F, Moldave K, eds. Methods in enzymology. 1984:99-115
67. 23 residue affects the aggregation properties of Alzheimer amyloid β protein analogues. J. Biol Chem 1994;269: 10205-8
68. Sparks DL, Schaff SW, Liu H, et al. Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in nondemented individuals with the apolipoprotein E4 allele: Comparison to confirmed Alzheimer's disease patients. J Neurological Sci 1996;138: 97-104
69. Haass C, Hung AY, Schlossmacher MG, Teplow DB, Selkoe DJ. Beta-amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. J Biol Chem 1993;268:3021-24
70. Busciglio J, Gabuzda D, Matsudaira P, Yankner B. Generation of β-amyloid in the secretory pathway in neuronal and nonneuronal cells. PNAS USA 1993;90:2092-96
71. Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996;23:4436-40
72. Wild-Bode C, Yamazaki T, Capell A, et al. Intracellular generation and accumulation of amyloid β-peptide terminating at amino acid 42. J Biol Chem 1997;272:16085-88
73. Turner RS, Suzuki N, Chyung AS, Younkin SG, Lee VM. Amyloids beta 40 and beta 42 are generated intracellularly in cultured human neurons and their secretion increases with maturation. J Biol Chem 1996;271:8966-70
74. Klafki H, Abramowski D, Swoboda R, Paganetti PA, Staufenbiel M. The carboxyl termini of beta-amyloid peptides 1-40 and 1-42 are generated by distinct gamma-secretase activities. J Biol Chem 1996;271:28655-59
75. LeBlanc AC, Papadopoulos M, Belair C, et al. Processing of amyloid precursor protein in human primary neuron and astrocyte cultures. J Neurochem 1997;68:1183-90
76. Haass C, Koo EH, Teplow DB, Selkoe DJ. Polarized secretion of beta-amyloid precursor protein and amyloid beta-peptide in MDCK cells. PNAS 1994;91(4):1564-68
77. Podlisny MB, Ostaszewski BL, Squazzo SL, et al. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995;270:9564-70
78. Haass C, Hung AY, Selkoe DJ, Teplow DB. Mutations associated with a locus for Familial Alzheimer's disease result in alternative processing of amyloid β-precursor protein. J Biol Chem 1994;269: 17741-48